Advances and controversies in the diagnosis and management of medullary thyroid carcinoma (Q41543512)

2 October 2017

1 reference

title

Advances and controversies in the diagnosis and management of medullary thyroid carcinoma (English)

1 reference

2 October 2017

Heshmati HM

1

1 reference

2 October 2017

Gharib H

series ordinal

2

1 reference

2 October 2017

van Heerden JA

series ordinal

3

1 reference

2 October 2017

Sizemore GW

series ordinal

4

1 reference

2 October 2017

language of work or name

English

0 references

publication date

1 July 1997

1 reference

American Journal of Medicine

2 October 2017

1 reference

2 October 2017

103

1 reference

2 October 2017

1

1 reference

2 October 2017

60-69

1 reference

Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity

2 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Medullary thyroid carcinoma: recent advances and management update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

RET proto-oncogene mutations in French MEN 2A and FMTC families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

RET gene and its implications for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

The RET proto-oncogene and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

The association of pheochromocytoma with carcinoma of the thyroid gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Medullary carcinoma of the thyroid gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Pheochromocytoma in multiple endocrine neoplasia type 2: European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Primary hyperparathyroidism in multiple endocrine neoplasia type 2A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

GDNF signalling through the Ret receptor tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC: s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Mutation of theRET protooncogene in sporadic medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

The Pathology of Medullary Carcinoma of the Thyroid: Review of the Literature and Personal Experience on 62 Cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Genetic screening for multiple endocrine neoplasia type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Direct, non-radioactive detection of mutations in Multiple Endocrine Neoplasia Type 2A families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Determination of silica-purified plasma calcitonin for the detection and management of medullary thyroid carcinoma: comparison of two provocative tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European Community Concerted Action: Medullary Thyroid Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Clinical performance of an extraction calcitonin radioimmunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Medullary carcinoma in children. Results of early detection and surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Somatostatin-Receptor Imaging of Medullary Thyroid Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Results of postoperative radiation therapy in medullary carcinoma of the thyroid: A retrospective study by the French Federation of Cancer Institutes - The Radiotherapy Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Radioactive iodine in the treatment of medullary carcinoma of the thyroid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900024-7

10.1016/S0002-9343(97)00024-7

7 January 2021

Identifiers

DOI

1 reference

2 October 2017

1 reference